8-K: Apogee Therapeutics Announces Promising Phase 1 Data for APG777, Accelerates Development Plans

Apogee Therapeutics has released positive interim Phase 1 data for its drug candidate APG777, showing a favorable safety profile and extended half-life, leading to accelerated Phase 2 trial plans.

Summary

• Apogee Therapeutics has shared interim results from its Phase 1 trial of APG777, an antibody targeting IL-13, in healthy volunteers.
• The trial demonstrated that APG777 was well-tolerated with a half-life of approximately 75 days, significantly longer than lebrikizumab.
• APG777 showed dose-proportional increases in exposure and achieved near-complete suppression of pSTAT6 and TARC biomarkers for about 3 months.
• The company plans to initiate a Phase 2 trial in atopic dermatitis (AD) in the first half of 2024, combining Phase 2a and 2b elements for faster development.
• The Phase 2 trial will test higher induction doses of APG777, aiming for 30-40% greater exposure than lebrikizumab, with the potential for 3or 6-month maintenance dosing.
• Apogee is also advancing other pipeline programs, including APG808 for COPD and APG990/222 targeting OX40L, with plans for Phase 1 trials in 2024.
• The company believes APG777 has the potential to be a leading product in the atopic dermatitis market, which is projected to be over $50 billion.

Sentiment

Score: 8

Explanation: The document presents very positive interim Phase 1 data for APG777, with a clear path to Phase 2 trials and a strong focus on addressing unmet needs in the I&I space. The company's pipeline and experienced management team further contribute to a positive outlook.

Positives

• APG777 has a significantly longer half-life of approximately 75 days compared to lebrikizumab, potentially allowing for less frequent dosing.
• The drug showed strong biomarker suppression, indicating effective target engagement and potential for clinical efficacy.
• The Phase 2 trial design combines Phase 2a and 2b elements, which could accelerate the development timeline.
• The planned higher induction doses of APG777 could lead to improved clinical responses compared to existing treatments.
• The potential for 3or 6-month maintenance dosing could significantly improve patient convenience and compliance.
• Apogee has a pipeline of other promising drug candidates targeting different inflammatory pathways, indicating a broad approach to I&I diseases.
• The company has an experienced management team and board of directors.

Negatives

• The data presented is from an interim analysis of a Phase 1 trial in healthy volunteers, and the results may not directly translate to patients with atopic dermatitis.
• The Phase 2 trial is still in the planning stages, and the final design and dosing regimens may change.
• The company is still in the early stages of development, and there is no guarantee that the drug candidates will be successful in later-stage trials.
• The atopic dermatitis market is competitive, and Apogee will need to demonstrate a clear advantage over existing treatments to gain market share.
• The company is relying on modeled data for exposure comparisons, and actual clinical results may vary.

Risks

• Clinical trial results may not meet expectations, and the drug candidates may not be approved by regulatory agencies.
• The company may face challenges in manufacturing and scaling up production of its drug candidates.
• Competition from other companies developing treatments for inflammatory and immune diseases could impact Apogee's market share.
• The company may need to raise additional capital to fund its research and development activities.
• There are risks associated with relying on modeled data for exposure comparisons, and actual clinical results may vary.
• The company is subject to risks associated with the development of novel therapeutics, including unexpected adverse events or safety concerns.

Future Outlook

Apogee plans to initiate a Phase 2 trial for APG777 in atopic dermatitis in the first half of 2024, with topline data expected in the second half of 2025. They also plan to advance other pipeline programs, including APG808 for COPD and APG990/222 targeting OX40L. The company aims to become a leader in I&I therapeutics.

Management Comments

• Apogee plans to reshape the current standard of care for inflammatory and immune diseases.
• The company is focused on developing differentiated biologics with known biologic drivers.
• Apogee is refusing to stop at good enough and is prioritizing treatments for atopic dermatitis, asthma, and COPD.
• The initial Phase 1 data for APG777 has exceeded all trial objectives.
• The company believes APG777 has the potential to be a best-in-class antibody.

Industry Context

This announcement comes as the market for biologics in inflammatory and immune diseases is growing rapidly. The company is positioning APG777 as a potential competitor to existing treatments like lebrikizumab and Dupixent, with the goal of providing less frequent dosing and potentially improved efficacy. The focus on atopic dermatitis, asthma, and COPD aligns with the significant unmet needs in these areas.

Comparison to Industry Standards

• APG777 is being compared to lebrikizumab, with the goal of achieving similar or better efficacy with less frequent dosing.
• The company is aiming for 30-40% higher exposure in induction compared to lebrikizumab, which could lead to improved clinical responses.
• The half-life of APG777 is approximately 75 days, which is significantly longer than the 18 days observed for lebrikizumab in NHP studies.
• APG808 is being compared to Dupixent, with the goal of achieving similar or better efficacy with less frequent dosing.
• The half-life of APG808 is approximately 26 days in NHP studies, which is significantly longer than the 12 days observed for Dupixent.
• The company is using Skyrizi in psoriasis as an example of how quarterly dosing can lead to market leadership.
• The company is comparing the efficacy of APG777 to other biologics in AD, such as Dupixent and Adbry, noting that they have similar efficacy but require more frequent dosing.

Stakeholder Impact

• Shareholders: The positive clinical data and accelerated development plans are likely to be viewed favorably by investors.
• Patients: The potential for less frequent dosing and improved efficacy could significantly benefit patients with atopic dermatitis and other I&I diseases.
• Employees: The company's progress and growth plans could create new opportunities for employees.
• Customers: The company's focus on developing differentiated biologics could lead to new treatment options for healthcare providers.
• Suppliers: The company's growth could lead to increased demand for suppliers of materials and services.

Next Steps

• Initiate Phase 2 trial for APG777 in atopic dermatitis in 1H 2024.
• Present APG808 safety and PK data in 2H 2024.
• Initiate Phase 1 trial for APG808 in healthy volunteers in 1H 2024.
• Initiate Phase 1 trial for APG990/222 in healthy volunteers in 2025.
• Disclose additional indications for APG777.

Key Dates

Keywords

APG777, Atopic Dermatitis, IL-13, Phase 1, Phase 2, Half-life, Biomarkers, Lebrikizumab, Inflammatory Diseases, Immunology, COPD, APG808, OX40L, APG990, APG222